| Name | Title | Contact Details |
|---|---|---|
Brian Comp |
Vice President of Information Technology | Profile |
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Cardiovascular Systems, Inc. is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Western Allergy Services Ltd is a Victoria, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Greenrise is a Canadian publicly traded corporation with its representative office located in Hamburg, Germany and operates in the medical and CBD cannabis markets in Germany.
F-star is a clinical-stage biopharmaceutical company committed to delivering life-changing treatments to cancer patients.